Back to top
more

Syndax Pharmaceuticals (SNDX)

(Real Time Quote from BATS)

$20.76 USD

20.76
1,551,927

+1.07 (5.43%)

Updated Nov 6, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

    Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

    ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

      The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

      The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

        Why These 4 Biotech Stocks May Not Lose Momentum Soon

        The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.

          Why Earnings Season Could Be Great for Syndax Pharmaceuticals (SNDX)

          Syndax Pharmaceuticals (SNDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

            Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

            Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.

              Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?

              Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.

                What's in Store for Puma (PBYI) this Earnings Season?

                Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.

                  What's in Store for Arena (ARNA) this Earnings Season?

                  Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.

                    Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?

                    ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.

                      Repros (RPRX) Q2 Earnings: What's in Store for the Stock?

                      Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.

                        Can Ligand (LGND) Pull a Surprise This Earnings Season?

                        Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

                          GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?

                          Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.

                            Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?

                            Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.

                              What's in the Cards for Adverum (ADVM) this Earnings Season?

                              Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                                What's in the Cards for Merrimack (MACK) in Q1 Earnings?

                                Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations

                                  Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?

                                  Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.

                                    Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?

                                    Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.

                                      Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

                                      Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

                                        Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?

                                        Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.

                                          Keryx (KERX) Q4 Earnings: What's in Store for the Stock?

                                          Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.

                                            ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?

                                            ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.

                                              Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

                                              Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.